Alimentary Pharmacology and Therapeutics
Издатель: Wiley · ISSN 02692813 · 92 статей
- Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis: A Real‐World Propensity Score‐Matched Study From the Autoimmune gastRitis Italian netwOrk Study grOup
- Letter: Calendar Era or Antiviral Choice—What Explains the Survival Benefit of Tenofovir Disoproxil Fumarate After Hepatocellular Carcinoma Resection?
- Letter: The Microbiome‐Mediated Impact of Proton Pump Inhibitors on Spontaneous Bacterial Peritonitis
- Letter: Calendar Era or Antiviral Choice–What Explains the Survival Benefit of Tenofovir Disoproxil Fumarate After Hepatocellular Carcinoma Resection? Authors' Reply
- Letter: The Microbiome‐Mediated Impact of Proton Pump Inhibitors on Spontaneous Bacterial Peritonitis—Authors' Reply
- Letter: Optimising Patient Selection for TACE Plus Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma
- Letter: Rethinking Washout Thresholds for Immune Checkpoint Inhibitors Before Liver Transplantation
- Letter: Fecal VOCs in Lynch Syndrome: Sample Stability, Specificity and Statistical Validation
- Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
- Letter: Methodological Caveats in Zhang et al.–Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension
- Systematic Review: Inclusion of Patients With Difficult‐to‐Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies
- Meta‐Analysis: The Placebo Response in Modern Treatments for Cholestatic Pruritus: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
- Review Article: Beyond the Therapeutic Ceiling in Inflammatory Bowel Disease—Mechanism‐Based Positioning and Emerging Therapeutic Strategies
- Issue Information
- Editorial: Treatment Sequencing in Inflammatory Bowel Disease: Does the Line Matter More Than the Mechanism?
- Editorial: MetALD‐ALD Prediction Index—A Scalable Biomarker for Alcohol Phenotyping Beyond PEth
- Editorial: Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis
- Editorial: MetALD‐ALD Prediction Index—A Scalable Biomarker for Alcohol Phenotyping Beyond PEth. Authors' Reply
- Editorial: Treatment Sequencing in Inflammatory Bowel Disease—Does the Line Matter More Than the Mechanism? Authors' Reply
- Editorial: Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis—Authors' Reply
- Editorial: Refractory Eosinophilic Oesophagitis—True Resistance or Suboptimal Management?
- Editorial: Regorafenib Plus Nivolumab in Advanced Hepatocellular Carcinoma—A Step Toward Mechanism‐Guided Second‐Line Therapy
- Letter: Timing Matters—Interpreting Colonic Gas Reduction With Gel‐Forming Fibres. Authors' Reply
-
Meta‐Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis
ABSTRACT Background Inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC) is a distinct phenotype (PSC‐IBD). Data on the safety and effectiveness of advanced IBD therapies on IBD outcomes in PSC‐IBD...
- Editorial: PCABs Are Better Than PPIs for Treating High‐Grade Peptic Oesophagitis
-
Eosinophilic Oesophagitis and Incidence of Gastrointestinal Cancer: A Population‐Based Cohort Study
ABSTRACT Background Evidence concerning gastrointestinal cancer risk after eosinophilic oesophagitis (EoE) diagnosis is limited. Aims To examine the association between EoE and incident gastrointestinal cancer in a population‐based...
- Letter: Diagnostic Assessment and Temporal Trends in Non‐Helicobacter pylori, Non‐NSAID Bleeding Ulcers
- Editorial: Taking a Different Route–Navigating the Switch From Intravenous to Subcutaneous Vedolizumab. Authors' Reply
- Reply to “Letter: From Genetic Association to Clinical Prediction in Chronic Hepatitis D” and “Letter: Interpreting HLA‐A*11:01 and Persistent HDV Viraemia in the Context of Host, Viral and Treatment Heterogeneity”
- Editorial: “Host Innate Immunity Reaches the Clinic—The Laboratory of Genetics and Physiology Protein 2 (LGP2) Q425R Variant and Severity of Chronic Hepatitis Delta: Authors' Reply”